PubMed

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, Moir S, Malaspina A, Morre M, Buffet R, Silvestri G, Lederman MM; ACTG 5214 Study Team.

Blood. 2009 Jun 18;113(25):6304-14. Epub 2009 Apr 20.PMID: 19380868 [PubMed - indexed for MEDLINE]Related articles

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52.PMID: 18771406 [PubMed - indexed for MEDLINE]Related articles

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA; International AIDS Society-USA.

JAMA. 2008 Aug 6;300(5):555-70.PMID: 18677028 [PubMed - indexed for MEDLINE]Related articlesFree article

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

Smith KY, Weinberg WG, Dejesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; ALERT (COL103952) Study Team.

AIDS Res Ther. 2008 Mar 28;5:5.PMID: 18373851 [PubMed]Related articlesFree article

Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.

Higgins N, Zingman BS, Slish J, Reichman RC, Fischl MA, Gripshover B, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD.

Am J Addict. 2007 Nov-Dec;16(6):488-94.PMID: 18058416 [PubMed - indexed for MEDLINE]Related articles

Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.

Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, Long MC, Kuritzkes DR, Sommadossi JP.

Antivir Ther. 2007;12(6):981-6.PMID: 17926654 [PubMed - indexed for MEDLINE]Related articles

Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD.

Ther Drug Monit. 2007 Oct;29(5):560-5.PMID: 17898644 [PubMed - indexed for MEDLINE]Related articles

Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection.

Morse GD, Fischl MA, Shelton MJ, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW.

Clin Drug Investig. 2003;23(4):255-61.PMID: 17535038 [PubMed - in process]Related articles

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F; for the AIDS Clinical Trials Group (ACTG).

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):193-200.PMID: 17527093 [PubMed - indexed for MEDLINE]Related articles

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.

DiFrancesco R, Fischl MA, Donnelly J, Zingman BS, McCance-Katz EF, Moody DE, Reichman RC, Gripshover B, Morse GD.

J Pharm Biomed Anal. 2007 May 9;44(1):188-95. Epub 2007 Feb 16.PMID: 17391891 [PubMed - indexed for MEDLINE]Related articles

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD.

Pharmacogenomics. 2007 Mar;8(3):227-35.PMID: 17324111 [PubMed - indexed for MEDLINE]Related articles

Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.

Keil K, Hochreitter J, DiFrancesco R, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Morse GD.

Ther Drug Monit. 2007 Feb;29(1):103-9.PMID: 17304157 [PubMed - indexed for MEDLINE]Related articles

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.

Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R.

AIDS. 2007 Jan 30;21(3):325-33.PMID: 17255739 [PubMed - indexed for MEDLINE]Related articles

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel.

Top HIV Med. 2006 Aug-Sep;14(3):827-43.PMID: 17016878 [PubMed]Related articlesFree article

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel.

JAMA. 2006 Aug 16;296(7):827-43.PMID: 16905788 [PubMed - indexed for MEDLINE]Related articlesFree article

Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial.

Krown SE, Lee JY, Lin L, Fischl MA, Ambinder R, Von Roenn JH.

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53.PMID: 16394845 [PubMed - indexed for MEDLINE]Related articles

A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.

Collier AC, Ribaudo H, Mukherjee AL, Feinberg J, Fischl MA, Chesney M; Adult AIDS Clinical Trials Group 746 Substudy Team.

J Infect Dis. 2005 Oct 15;192(8):1398-406. Epub 2005 Sep 14.PMID: 16170757 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.

Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team.

Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61.PMID: 16048984 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.

Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA; AIDS Clinical Trials Group Protocol 388.

Clin Infect Dis. 2004 Aug 15;39(4):552-8. Epub 2004 Jul 30.PMID: 15356820 [PubMed - indexed for MEDLINE]Related articles

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA.

JAMA. 2004 Jul 14;292(2):251-65.PMID: 15249575 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.

DiCenzo R, Forrest A, Fischl MA, Collier A, Feinberg J, Ribaudo H, DiFrancecso R, Morse GD; AIDS Clinical Trials Group 388/733/5060 Study Team.

Antimicrob Agents Chemother. 2004 Mar;48(3):918-23.PMID: 14982784 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V; ACTG 372B/D Study Team.

Antivir Ther. 2003 Dec;8(6):507-18. No abstract available. PMID: 14760884 [PubMed - indexed for MEDLINE]Related articles

Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease.

Malhotra U, Bosch RJ, Chan E, Wang R, Fischl MA, Collier AC, McElrath MJ.

J Infect Dis. 2004 Feb 1;189(3):515-9. Epub 2004 Jan 16.PMID: 14745710 [PubMed - indexed for MEDLINE]Related articles

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2293-303.PMID: 14668455 [PubMed - indexed for MEDLINE]Related articlesFree article

Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.

Fischl MA, Burnside AE Jr, Farthing CE, Thompson MA, Bellos NC, Williams VC, Kauf TL, Wannamaker PG, Shaefer MS; ESS40005 Study Team.

Pharmacotherapy. 2003 Nov;23(11):1432-40.PMID: 14620390 [PubMed - indexed for MEDLINE]Related articles

Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.

Hirsch MS, Steigbigel RT, Staszewski S, McMahon D, Fischl MA, Hirschel B, Squires K, DiNubile MJ, Harvey CM, Chen J, Leavitt RY; Protocol 039 Study Group.

Clin Infect Dis. 2003 Oct 15;37(8):1119-24. Epub 2003 Sep 18.PMID: 14523778 [PubMed - indexed for MEDLINE]Related articles

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ Jr, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH; Adult AIDS Clinical Trials Group 388 Study Team.

J Infect Dis. 2003 Sep 1;188(5):625-34. Epub 2003 Aug 15. Erratum in: J Infect Dis. 2003 Oct 1;188(7):1083. PMID: 12934177 [PubMed - indexed for MEDLINE]Related articles

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD; Adult AIDS Clinical Trials Group Protocol 368/886 Study Team.

Antimicrob Agents Chemother. 2003 Jun;47(6):1929-35.PMID: 12760869 [PubMed - indexed for MEDLINE]Related articlesFree article

Multidrug-resistant tuberculous meningitis in patients with AIDS.

Daikos GL, Cleary T, Rodriguez A, Fischl MA.

Int J Tuberc Lung Dis. 2003 Apr;7(4):394-8.PMID: 12729347 [PubMed - indexed for MEDLINE]Related articles

Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.

Young B, Fischl MA, Wilson HM, Finn TS, Jensen EH, DiNubile MJ, Zeldin RK.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):478-82.PMID: 12473835 [PubMed - indexed for MEDLINE]Related articles

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA.

JAMA. 2002 Jul 10;288(2):222-35. Review. Erratum in: JAMA. 2003 Jan-Feb;11(1):32. PMID: 12095387 [PubMed - indexed for MEDLINE]Related articles

Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.

Demeter LM, Bosch RJ, Coombs RW, Fiscus S, Bremer J, Johnson VA, Erice A, Jackson JB, Spector SA, Squires KM, Fischl MA, Hughes MD, Hammer SM.

J Clin Microbiol. 2002 Jun;40(6):2089-94.PMID: 12037070 [PubMed - indexed for MEDLINE]Related articlesFree article

Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.

Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S; CNA3003 International Study Team.

Antivir Ther. 2002 Mar;7(1):43-51.PMID: 12008787 [PubMed - indexed for MEDLINE]Related articles

Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.

Kirkland LR, Fischl MA, Tashima KT, Paar D, Gensler T, Graham NM, Gao H, Rosenzweig JR, McClernon DR, Pittman G, Hessenthaler SM, Hernandez JE; NZTA4007 Study Team.

Clin Infect Dis. 2002 Feb 15;34(4):511-8. Epub 2002 Jan 4.PMID: 11797179 [PubMed - indexed for MEDLINE]Related articles

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.PMID: 11730396 [PubMed - indexed for MEDLINE]Related articlesFree article

Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?

Arduino JM, Fischl MA, Stanley K, Collier AC, Spiegelman D.

AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1099-105.PMID: 11522179 [PubMed - indexed for MEDLINE]Related articles

Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D.

Antiviral Res. 2000 Jan;45(1):47-58.PMID: 10774589 [PubMed - indexed for MEDLINE]Related articles

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC.

Antimicrob Agents Chemother. 2000 Mar;44(3):794-7.PMID: 10681363 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA.

JAMA. 2000 Jan 19;283(3):381-90. Review.PMID: 10647802 [PubMed - indexed for MEDLINE]Related articles

Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.

Fischl MA.

AIDS. 1999 Sep;13 Suppl 1:S49-59. Review.PMID: 10546785 [PubMed - indexed for MEDLINE]Related articles

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C.

AIDS. 1999 Apr 16;13(6):685-94.PMID: 10397563 [PubMed - indexed for MEDLINE]Related articles

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M, Sommadossi JP.

Antimicrob Agents Chemother. 1999 Jan;43(1):121-8.PMID: 9869576 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.

Henry K, Erice A, Tierney C, Balfour HH Jr, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):339-49.PMID: 9833742 [PubMed - indexed for MEDLINE]Related articles

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group.

Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT.

AIDS. 1998 Oct 1;12(14):1823-32.PMID: 9792383 [PubMed - indexed for MEDLINE]Related articles

Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.

Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, Timpone J Jr, Wathen LK, Nevin T, Resnick L, Batts DH, Reichman RC.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):135-44.PMID: 9768622 [PubMed - indexed for MEDLINE]Related articles

Disseminated miliary tuberculosis of the skin in patients with AIDS: report of four cases.

Daikos GL, Uttamchandani RB, Tuda C, Fischl MA, Miller N, Cleary T, Saldana MJ.

Clin Infect Dis. 1998 Jul;27(1):205-8.PMID: 9675477 [PubMed - indexed for MEDLINE]Related articles

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH.

J Clin Oncol. 1998 Jul;16(7):2445-51.PMID: 9667262 [PubMed - indexed for MEDLINE]Related articles

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA.

JAMA. 1998 Jul 1;280(1):78-86. Review.PMID: 9660368 [PubMed - indexed for MEDLINE]Related articles

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.

Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS.

J Infect Dis. 1998 Jan;177(1):40-7.PMID: 9419168 [PubMed - indexed for MEDLINE]Related articles

Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.

Fischl MA, Richman DD, Saag M, Meng TC, Squires KE, Holden-Wiltse J, Meehan PM.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 1;16(4):247-53.PMID: 9402071 [PubMed - indexed for MEDLINE]Related articles